Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A poorly differentiated neuroendocrine carcinoma that arises from the breast. It is characterized by the presence of large neuroendocrine cells and high mitotic activity.
Biomarker and diagnostic research for breast large cell neuroendocrine carcinoma has been reported in the published literature.
No clinical trials have been registered for breast large cell neuroendocrine carcinoma.
28 publications have been identified in PubMed for breast large cell neuroendocrine carcinoma. Research spans Case Report / Case Series (57%), Review / Meta-Analysis (21%), and Diagnostic / Biomarker (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 16 | 57% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 9:41 PM UTC
Research summaries
6 |
21% |
Testing and diagnosis research | 3 | 11% |
Clinical study results | 1 | 4% |
Laboratory research | 1 | 4% |
Disease patterns and progression | 1 | 4% |
Zyani K (2026). [PMID: 41566083](https://pubmed.ncbi.nlm.nih.gov/41566083/). *Virchows Archiv : an international journal of pathology*. [Case Report / Case Series]
Ciarka A (2026). [PMID: 41819300](https://pubmed.ncbi.nlm.nih.gov/41819300/). *Critical reviews in oncology/hematology*. [Review / Meta-Analysis]
Pavlíčková K (2026). [PMID: 41588454](https://pubmed.ncbi.nlm.nih.gov/41588454/). *Diagnostic pathology*. [Diagnostic / Biomarker]
Zhu S (2026). [PMID: 41768230](https://pubmed.ncbi.nlm.nih.gov/41768230/). *Frontiers in oncology*. [Case Report / Case Series]
Xu P (2026). [PMID: 41768248](https://pubmed.ncbi.nlm.nih.gov/41768248/). *Frontiers in oncology*. [Case Report / Case Series]
Nezhad HZ (2026). [PMID: 42157024](https://pubmed.ncbi.nlm.nih.gov/42157024/). *Cancer Rep (Hoboken)*. [Case Report / Case Series]
Hoda RS (2025). [PMID: 40480318](https://pubmed.ncbi.nlm.nih.gov/40480318/). *Human pathology*. [Diagnostic / Biomarker]
Albayrak NE (2025). [PMID: 40909459](https://pubmed.ncbi.nlm.nih.gov/40909459/). *Frontiers in medicine*. [Review / Meta-Analysis]
Cui W (2025). [PMID: 39635966](https://pubmed.ncbi.nlm.nih.gov/39635966/). *Diagnostic cytopathology*. [Diagnostic / Biomarker]
Hickey K (2025). [PMID: 40277762](https://pubmed.ncbi.nlm.nih.gov/40277762/). *Current oncology (Toronto, Ont.)*. [Case Report / Case Series]